Bevixa 100 IV infusion: Each vial contains Bevacizumab INN 100 mg in 4 ml sterile solution for IV infusion
Bevixa 400 IV infusion: Each vial contains Bevacizumab INN 400 mg in 16 ml sterile solution for IV infusion
Bevacizumab is a sterile solution for intravenous infusion. It is a recombinant humanized monoclonal IgG1 antibody that binds to and inhibits the biologic activity of human vascular endothelial growth factor (VEGF) in in vitro and in vivo assay systems.
Bevacizumab is a vascular endothelial growth factor-specific angiogenesis inhibitor indicated for the treatment of
• Metastatic colorectal cancer, with intravenous 5-fluorouracil–based chemotherapy for first- or second-line treatment
• Metastatic colorectal cancer, with fluoropyrimidine- irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy for second-line treatment in patients who have progressed on a first-line Bevacizumab containing regimen
• Non-squamous non-small cell lung cancer, with carboplatin and paclitaxel for first line treatment of unresectable, locally advanced, recurrent or metastatic disease.
• Glioblastoma, as a single agent for adult patients with progressive disease following prior therapy
• Effectiveness based on improvement in objective response rate. No data available demonstrating improvement in disease-related symptoms or survival with Bevacizumab.
• Metastatic renal cell carcinoma with interferon alfa Cervical cancer, in combination with paclitaxel and cisplatin or paclitaxel and topotecan in persistent, recurrent, or metastatic disease
• Platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, in combination with paclitaxel, pegylated liposomal doxorubicin or topotecan
Limitation of Use: Bevacizumab is not indicated for adjuvant treatment of colon cancer.
Dosage & Administration
Bevacizumab should not be administered as an IV push or bolus
Bevacizumab should not be initiated for 28 days following major surgery and until surgical wound is fully healed
• Metastatic colorectal cancer
5 mg/kg IV every 2 weeks with bolus-IFL
10 mg/kg IV every 2 weeks with FOLFOX4
5 mg/kg IV every 2 weeks or 7.5 mg/kg IV every 3 weeks with fluoropyrimidine-irinotecan or fluoropyrimidine-oxaliplatin based chemotherapy after progression on a first-line Bevacizumab containing regimen
• Non-squamous non-small cell lung cancer
15 mg/kg IV every 3 weeks with carboplatin/paclitaxel
10 mg/kg IV every 2 weeks
• Metastatic renal cell carcinoma (mRCC)
10 mg/kg IV every 2 weeks with interferon alfa
• Persistent, recurrent, or metastatic carcinoma of the cervix
15 mg/kg IV every 3 weeks with paclitaxel/cisplatin or paclitaxel/topotecan
• Platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer
10 mg/kg IV every 2 weeks with paclitaxel, pegylated liposomal doxorubicin or weekly topotecan 15 mg/kg IV every 3 weeks with topotecan given every 3 weeks
Most common adverse reactions incidence (> 10% and at least twice the control arm rate) are epistaxis, headache, hypertension, rhinitis, proteinuria, taste alteration, dry skin, rectal hemorrhage, lacrimation disorder, back pain and exfoliative dermatitis. Some of the adverse reactions are commonly seen with chemotherapy; however, Bevacizumab may exacerbate these reactions when combined with chemotherapeutic agents. Examples include palmar-plantar erythrodysaesthesia syndrome with pegylated liposomal doxorubicin or capecitabine peripheral sensory neuropathy with paclitaxel or oxaliplatin, and nail disorders or alopecia with paclitaxel.
Perforation or Fistula: Bevacizumab should be discontinued if perforation or fistula occurs.
Arterial Thromboembolic Events (e.g., myocardial infarction, cerebral infarction): Bevacizumab should be discontinued for severe ATE.
Venous Thromboembolic Events: Bevacizumab should be discontinued for life-threatening VTE
Hypertension: Monitor blood pressure and treat hypertension. Temporarily suspend Avastin if not medically controlled. Bevacizumab should be discontinued for hypertensive crisis or hypertensive encephalopathy
Posterior Reversible Encephalopathy Syndrome (PRES): Bevacizumab should be discontinued
Proteinuria: Urine protein should be monitored. Bevacizumab should be discontinued for nephrotic syndrome. Bevacizumab should be temporarily discontinued for moderate proteinuria.
Infusion Reactions: Bevacizumab should be stopped in case of severe infusion reactions.
Embryo-fetal Toxicity: Females should be advised of the potential risk to a fetus and the need for use of effective contraception
Ovarian Failure: Females should be advised of the potential risk
Use in Pregnancy & Lactation
Bevacizumab may cause fetal harm based on findings from animal studies and the drug’s mechanism of action. Pregnant women should be advised of the potential risk to a fetus.
No data are available regarding the presence of Bevacizumab in human milk, the effects on the breast fed infant, or the effects on milk production. Because of the potential for serious adverse reactions in breastfed infants from Bevacizumab, nursing woman should be advised that breastfeeding is not recommended during treatment with Bevacizumab.
Safety and effectiveness of Bevacizumab have not been established in pediatric patients.
A drug interaction study was performed in which Irinotecan was administered as part of the FOLFIRI regimen with or without Bevacizumab. The results demonstrated no significant effect of Bevacizumab on the pharmacokinetics of Irinotecan or its active metabolite SN38.
Bevixa 100 IV infusion: Each box contains 1 vial of Bevacizumab 100 mg in 4 ml sterile solution for IV infusion.
Bevixa 400 IV infusion: Each box contains 1 vial of Bevacizumab 400 mg in 16 ml sterile solution for IV infusion.